Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of TS-172 in Hemodialysis Patients
NCT06849778Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Mar 2025
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TS-172 in hyperphosphatemia, sponsored by Taisho Pharmaceutical. Primary endpoints: Concentration of unchanged form in plasma at Day 9 and Concentration of major metabolites in plasma at Day 9. Started Mar 2025; status: completed.
02
Drugs
TS-172
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT06849778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06849778.